Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Akari Therapeutics Plc
A biotech company engineering antibody-drug conjugates—"smart bombs" that carry a toxin to cancer cells. Its twist is a payload called PH1 that disrupts how cancer cells splice their RNA, killing them and waking the immune system; its lead drug AKTX-101 targets the TROP2 protein on solid tumors. Akari was born in 2015 when Celsus Therapeutics absorbed Volution Immuno Pharmaceuticals and took a name meaning "light" in Japanese. Earlier it made Coversin, a drug derived from tick saliva.
Sponsored ADR
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 3.02 Unregistered Sales of Equity Securities · 9.01 Financial Statements and Exhibits
3.03 Material Modification to Rights of Security Holders · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders
1.01 Entry into a Material Definitive Agreement · 1.02 Termination of a Material Definitive Agreement · 3.02 Unregistered Sales of Equity Securities · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits